Cryo-Cell (CCEL) Chairman David Portnoy Transfers 600,191 Shares to Trust

What Happened

• David Portnoy, Chairman of the Board (10% owner), reported a transfer of 600,191 shares of Cryo-Cell common stock on August 5, 2026. The Form 4 shows a simultaneous disposition and acquisition (code J) of 600,191 shares at $1.33 per share (reported value ~$799,995). This reflects a transfer of the shares into the David Portnoy Irrevocable 2026 Trust and is not a typical open-market sale or purchase.

Key Details

• Transaction date: August 5, 2026; Form 4 filed August 7, 2026 (appears timely).
• Reported price/value: $1.33 per share; total reported value shown ~$799,995 (footnote clarifies actual loan proceeds = $800,000.26).
• Nature of transaction: Transfer to an irrevocable trust (code J). The Trust borrowed $800,000.26 in connection with the transfer; proceeds were used to satisfy Portnoy’s outstanding indebtedness. Portnoy personally guaranteed the Trust’s repayment obligations.
• Trustee and ownership: Deborah Portnoy (his spouse) is sole trustee. Portnoy is not a beneficiary, has no power to revoke the Trust, and disclaims beneficial ownership of the Trust-held shares except to the extent of any pecuniary interest.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote/price note: The $1.33 per-share figure equals loan proceeds divided by shares and "does not represent the fair market value" of the shares.

Context

• This transaction is a non-market transfer to a family trust secured by a loan, not a routine buy or sell reflecting market sentiment. For reporting purposes it shows both a disposition and acquisition (accounting for the transfer into the trust). As a 10% owner and Chairman, Portnoy’s transfer is governance/financial planning-related rather than an open-market trade.